RxDoctor Payments Data

Charles Ternent, MD

Colon & Rectal Surgery · Omaha, NENPI 1841289147

Payments from drug & device makers

What this record shows

This record is dominated by education: $4,000 of the $6,632 with a category attached, or 60.3%. Intuitive Surgical accounts for 74.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $3,710 and has fallen 85.1% since, to $554 in 2025.

$6,632in general payments, 2019–2025

Across 52 payments — averaging $127.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Davol Inc.$618
  • TELA Bio, Inc.$303
  • Virtual Incision Corporation$154
  • Johnson & Johnson$84
  • Mallinckrodt Enterprises LLC$73
  • plus $490 from 15 others
$36,344in research payments, 2019–2025

Across 8 payments — averaging $4543.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$18K
  • BD$11K
  • Cosette Pharmaceuticals Inc.$6K
  • Davol Inc.$2K

What the payments were for

  • Travel & lodging$190%
  • Food & beverage$2,61339%
  • Education$4,00060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colon & rectal surgery providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$146,556
Medicare patients
330
Services billed
885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,785
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl90$1,326
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates13$836
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl25$385
Neomycin Sulfate31$149
Metronidazole38$59

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →